1. Patient-reported Quality of Life After Breast-conserving Surgery With Radiotherapy Versus Mastectomy and Reconstruction.
- Author
-
Diao, Kevin, Xiudong Lei, Weiguo He, Jagsi, Reshma, Giordano, Sharon H., Peterson, Susan K., and Smith, Benjamin D.
- Abstract
Objective: To compare long-term quality of life (QOL) outcomes in breast cancer survivors who received breast-conserving surgery with radiotherapy (BCS+RT) with those who received a mastectomy and reconstructive surgery (Mast+Recon) without radiotherapy and identify other important factors. Background: The long-term differences in patient-reported QOL outcomes following BCS+RT and Mast+Recon are not well understood. Methods:We identified patients from the Texas Cancer Registry with stage 0--II breast cancer diagnosed in 2009--2014 after BCS+RT orMast+Recon without radiotherapy. Sampling was stratified by age and race and ethnicity. A paper survey was sent to 4800 patients which included validated BREAST-Q and PROMIS modules. Multivariable linear regression models were implemented for each outcome.Minimal clinically important difference for BREAST-Q and PROMIS modules, respectively, was 4 points and 2 points. Results: Of 1215 respondents (25.3% response rate), 631 received BCS +RT and 584 received Mast+Recon. The median interval from diagnosis to survey completion was 9 years. In adjusted analysis, Mast+Recon was associated with worse BREAST-Q psychosocial well-being (effect size: 3.80, P=0.04) and sexual well-being (effect size: 5.41, P=0.02), but better PROMIS physical function (effect size: 0.54, P=0.03) and similar BREAST-Q satisfaction with breasts, physical well-being, and PROMIS upper extremity function (P>0.05) compared with BCS+RT. Only the difference in sexual well-being reached clinical significance. Older (≥65) patients receiving BCS+RT and younger (< 50) patients receiving autologous Mast+Recon typically reported higher QOL scores. Receipt of chemotherapy was associated with detriments to multiple QOL domains. Conclusions: Patients who underwent Mast+Recon reported worse longterm sexual well-being compared with BCS+RT. Older patients derived a greater benefit from BCS+RT, while younger patients derived a greater benefit from Mast+Recon. These data inform preference-sensitive decision- making for women with early-stage breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF